Clinical Trial

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the recommended phase 2 dose of the drug Vorinostat in children, adolescents and young adults following allogeneic blood or marrow transplant (BMT) and determine whether the addition of Vorinostat to the standard graft versus host disease (GVHD) prophylaxis will reduce the incidence of GVHD.
Protocol Amendment History 21 amendments
This ClinicalTrials.gov record has been amended 21 times since 2019-02-13; most recent amendment 2026-01-23.
Status change: Recruiting → Active, Not Recruiting 2025-04-07
Status change: Not Yet Recruiting → Recruiting 2019-05-13
Trial Details
NCT Number NCT03842696
Lead Sponsor University of Michigan Rogel Cancer Center
Collaborators: National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS)
Conditions Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myelogenous Leukemia, Accelerated Phase, Chronic Myelogenous Leukemia, Blastic Phase, Myelodysplastic Syndromes, Mantle Cell Lymphoma, Follicular Lymphoma +4 more
Enrollment 43 participants
Start Date 2020-02-04
Primary Completion 2025-07-30 (estimated)
Study Completion 2026-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-27